Thursday, March 04, 2010 6:30:21 PM
Dear Eva Harris;
I am a NanoViricides shareholder and would like to contribute to your Dengue research efforts. How do I do that? Who do I make the check to and what is the address?
Thanks for all you do,
xxx
Eva Harris
to me
Dear Mr.xxx,
thank you very much for your email and for your interest in supporting our work. I am currently out of the country on a work trip, but will respond as best I can from here. We can receive donations at the University of California, Berkeley through a Gift account. The check can be made out to "Regents of the University of California" with "Eva Harris, Fund 43528/R43528000" on the Memo line, and should be accompanied by a letter like the draft below -- this way we can used the funds directly for our work on dengue.
Patricia W. Hosel, MPA
Assistant Dean
External Relations & Development
University of California, Berkeley
School of Public Health
417H University Hall
Berkeley, CA 94720-7360
Dear Ms Hosel,
Please find enclosed a cheque of $ xxx to provide unrestricted funds in support of Professor Eva Harris' research Fund 43528/R43528000 at the UC Berkeley School of Public Health.
Yours sincerely,
xxx
Very gratefully yours,
Eva Harris
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM